Humacyte (HUMA) News Today → Did Intel Just Dethrone Nvidia? (From Chaikin Analytics) (Ad) Free HUMA Stock Alerts $6.42 +0.94 (+17.15%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 1:07 PM | marketbeat.comHumacyte (NASDAQ:HUMA) Shares Gap Up to $5.48Humacyte (NASDAQ:HUMA) Shares Gap Up to $5.48May 14 at 10:45 AM | msn.comHumacyte extends gains as FDA reviews blood vessel productMay 13 at 7:39 PM | markets.businessinsider.comBenchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)May 13 at 7:39 PM | msn.comHumacyte, Inc. (NASDAQ:HUMA) Q1 2024 Earnings Call TranscriptMay 13 at 1:52 PM | marketbeat.comHumacyte (NASDAQ:HUMA) Hits New 12-Month High at $5.09Humacyte (NASDAQ:HUMA) Reaches New 52-Week High at $5.09May 13 at 10:32 AM | marketbeat.comHumacyte (NASDAQ:HUMA) Receives "Buy" Rating from BenchmarkBenchmark restated a "buy" rating and issued a $15.00 target price on shares of Humacyte in a research note on Monday.May 13 at 8:11 AM | finance.yahoo.comHumacyte Inc (HUMA) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...May 13 at 8:11 AM | finance.yahoo.comHumacyte to Participate at Upcoming Investor Conferences in MayMay 13 at 8:00 AM | globenewswire.comHumacyte to Participate at Upcoming Investor Conferences in MayMay 12 at 4:03 AM | americanbankingnews.comHumacyte (NASDAQ:HUMA) Trading 6.2% Higher May 11 at 12:23 AM | finance.yahoo.comQ1 2024 Humacyte Inc Earnings CallMay 10, 2024 | marketbeat.comHumacyte (NASDAQ:HUMA) Trading Up 6.2%Humacyte (NASDAQ:HUMA) Shares Up 6.2%May 10, 2024 | benzinga.comPeering Into Humacyte's Recent Short InterestMay 10, 2024 | finance.yahoo.comHumacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic AdvancesMay 10, 2024 | msn.comHumacyte GAAP EPS of -$0.29 misses by $0.06May 10, 2024 | globenewswire.comHumacyte First Quarter 2024 Financial Results and Business UpdateMay 9, 2024 | msn.comHumacyte Q1 2024 Earnings PreviewMay 9, 2024 | americanbankingnews.comHumacyte (HUMA) Scheduled to Post Earnings on FridayMay 7, 2024 | marketbeat.comHumacyte (HUMA) to Release Quarterly Earnings on FridayHumacyte (NASDAQ:HUMA) will be releasing earnings before the market opens on Friday, May 10, Zacks reports.May 6, 2024 | globenewswire.comHumacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024May 6, 2024 | americanbankingnews.comHead to Head Survey: Humacyte (NASDAQ:HUMA) vs. Cidara Therapeutics (NASDAQ:CDTX)May 1, 2024 | marketbeat.comHumacyte (NASDAQ:HUMA) Trading Up 7.4%Humacyte (NASDAQ:HUMA) Stock Price Up 7.4%April 20, 2024 | msn.comA U.S. Senator Just Bought this Tiny Stock – It’s Up 15% TodayApril 18, 2024 | msn.comA U.S. Senator Just Bought this Tiny Stock - It's Up 15% TodayApril 18, 2024 | benzinga.comAlly Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On ThursdayApril 18, 2024 | msn.comTuberville’s Trading Raises Questions: Senator Sells Put Options, Invests in Small Biotech Tied to Ukraine-Russia ConflictApril 17, 2024 | ca.investing.comU.S. Senator Tommy Tuberville Just Reported a Purchase of $HUMA stockApril 15, 2024 | finance.yahoo.comHumacyte, Inc. (HUMA) Interactive Stock Chart - Yahoo FinanceApril 8, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Humacyte (HUMA)April 4, 2024 | marketbeat.comResearch Analysts Set Expectations for Humacyte, Inc.'s FY2024 Earnings (NASDAQ:HUMA)Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Equities research analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for Humacyte in a research report issued to clients and investors on Monday, April 1st. Cantor Fitzgerald analyst K. Kluska now expects that the company wilApril 1, 2024 | marketbeat.comHumacyte's (HUMA) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and issued a $7.00 target price on shares of Humacyte in a research report on Monday.March 29, 2024 | marketbeat.comShort Interest in Humacyte, Inc. (NASDAQ:HUMA) Declines By 36.5%Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 3,780,000 shares, a drop of 36.5% from the February 29th total of 5,950,000 shares. Based on an average daily volume of 870,900 shares, the short-interest ratio is presently 4.3 days. Approximately 4.5% of the shares of the company are short sold.March 26, 2024 | globenewswire.comHumacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024March 25, 2024 | marketbeat.comHumacyte's (HUMA) "Buy" Rating Reiterated at BenchmarkBenchmark reaffirmed a "buy" rating and set a $15.00 price target on shares of Humacyte in a research report on Monday.March 23, 2024 | markets.businessinsider.comHumacyte’s Strong Outlook: Buy Rating Affirmed Amid Advancements and Market OpportunityMarch 23, 2024 | finance.yahoo.comQ4 2023 Humacyte Inc Earnings CallMarch 23, 2024 | marketbeat.comHumacyte (NASDAQ:HUMA) Posts Earnings ResultsHumacyte (NASDAQ:HUMA - Get Free Report) released its earnings results on Friday. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01. During the same period in the prior year, the company posted ($0.21) EPS.March 22, 2024 | markets.businessinsider.comBuy Rating for Humacyte: Anticipated FDA Approval and Strong Financials Signal Growth PotentialMarch 22, 2024 | investorplace.comHUMA Stock Earnings: Humacyte Meets EPS for Q4 2023March 22, 2024 | msn.comHumacyte GAAP EPS of -$0.24 in-lineMarch 22, 2024 | globenewswire.comHumacyte Fourth Quarter and Year End 2023 Financial Results and Business UpdateMarch 21, 2024 | markets.businessinsider.comWhat Wall Street expects from Humacyte's earningsMarch 18, 2024 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Sees Large Drop in Short InterestHumacyte, Inc. (NASDAQ:HUMA - Get Free Report) was the target of a large decline in short interest in the month of February. As of February 29th, there was short interest totalling 5,950,000 shares, a decline of 9.3% from the February 14th total of 6,560,000 shares. Based on an average daily volume of 781,400 shares, the short-interest ratio is currently 7.6 days. Currently, 7.0% of the shares of the company are short sold.March 18, 2024 | globenewswire.comHumacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024March 18, 2024 | ca.finance.yahoo.comHUMA Apr 2024 5.000 callMarch 4, 2024 | marketwatch.comHumacyte Shares Rise 10% on Common Stock OfferingMarch 1, 2024 | msn.comWhy Humacyte (HUMA) Shares Are FallingMarch 1, 2024 | globenewswire.comHumacyte, Inc. to Present at the TD Cowen 44th Annual Health Care ConferenceMarch 1, 2024 | msn.comHumacyte stock dips after pricing stock offering to raise $40.2MFebruary 29, 2024 | marketwatch.comHumacyte Shares Drop 19% After Proposed Public Offering News Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden to Drop BOMBSHELL June 13th? (Ad)Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th! Click here now to see his shocking evidence. HUMA Media Mentions By Week HUMA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HUMA News Sentiment▼-0.050.57▲Average Medical News Sentiment HUMA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HUMA Articles This Week▼222▲HUMA Articles Average Week Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VALN News Today PROK News Today ALEC News Today KYTX News Today CABA News Today EXAI News Today ALLO News Today EVLV News Today VYGR News Today CCCC News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HUMA) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsAmerica’s worst nightmare?Porter & CompanyCrypto Millionaire Says: “Buy This $11 AI Coin.”InvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
